BC
ARLZ

Broadfin Capital’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Broadfin Capital’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,034,103
Closed -$2.75M – 62
2017
Q2 		$2.75M Sell
2,034,103
-3,157,487
-61% -$4.56M 0.33% 43
2017
Q1 		$11.1M Buy
5,191,590
+400,000
+8% +$1.5M 1.35% 25
2016
Q4 		$21.1M Buy
4,791,590
+384,600
+9% +$1.83M 2.35% 13
2016
Q3 		$21.4M Buy
4,406,990
+300,000
+7% +$1.37M 1.92% 15
2016
Q2 		$13.6M Buy
4,106,990
+306,990
+8% +$1.16M 1.32% 21
2016
Q1 		$13.5M Buy
+3,800,000
New +$19.6M 1.3% 22

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return

Broadfin Capital's ARLZ Position: Q3 2017 in Review

Broadfin Capital sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2017, closing a stake of 2,034,103 shares — an estimated $2.75M sold.

Broadfin Capital first reported a position in ARLZ in Q1 2016 and held it in 6 quarters. The position peaked at $21.4M in Q3 2016. 59 funds tracked by Wall St. Rank hold ARLZ as of Q3 2017.

  • Broadfin Capital reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2017 after selling out during the quarter.
  • Broadfin Capital sold 2,034,103 Aralez Pharmaceuticals Inc. shares in Q3 2017, an estimated $2.75M.
  • Broadfin Capital first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 6 quarters.
  • Broadfin Capital's Aralez Pharmaceuticals Inc. position peaked at $21.4M in Q3 2016.
  • 59 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2017.

Based on Broadfin Capital's 13F filing for Q3 2017, filed 14 Nov 2017.